ACET vs. BEAM

Last updated Apr 1, 2026

Compare and contrast key facts about Adicet Bio, Inc. (ACET) and Beam Therapeutics Inc. (BEAM).

Performance

ACET vs. BEAM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Adicet Bio, Inc. (ACET) and Beam Therapeutics Inc. (BEAM). The values are adjusted to include any dividend payments, if applicable.

ACET vs. BEAM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
ACET Adicet Bio, Inc.	-19.12%	-45.30%	-49.10%	-78.86%	-48.89%	24.48%	43.88%
BEAM Beam Therapeutics Inc.	-14.03%	11.77%	-8.89%	-30.40%	-50.92%	-2.39%	335.41%

Fundamentals

Market Cap ACET : $46.93M BEAM : $2.50B
EPS ACET : -$19.17 BEAM : -$0.78
PB Ratio ACET : 0.29 BEAM : 2.02
Total Revenue (TTM) ACET : $0.00 BEAM : $25.63M
Gross Profit (TTM) ACET : $0.00 BEAM : -$284.71M
EBITDA (TTM) ACET : -$122.11M BEAM : -$352.98M

Returns By Period

In the year-to-date period, ACET achieves a -19.12% return, which is significantly lower than BEAM's -14.03% return.

ACET

• 1D: 11.46%
• 1M: -6.07%
• YTD: -19.12%
• 6M: -47.47%
• 1Y: -43.63%
• 3Y*: -58.04%
• 5Y*: -49.62%
• 10Y*: —

BEAM

• 1D: 8.81%
• 1M: -16.27%
• YTD: -14.03%
• 6M: -1.81%
• 1Y: 22.02%
• 3Y*: -8.02%
• 5Y*: -21.46%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ACET vs. BEAM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACET

ACET Risk / Return Rank: 19
ACET Sharpe Ratio Rank: 20
ACET Sortino Ratio Rank: 23
ACET Omega Ratio Rank: 24
ACET Calmar Ratio Rank: 14
ACET Martin Ratio Rank: 13

BEAM

BEAM Risk / Return Rank: 52
BEAM Sharpe Ratio Rank: 53
BEAM Sortino Ratio Rank: 57
BEAM Omega Ratio Rank: 54
BEAM Calmar Ratio Rank: 47
BEAM Martin Ratio Rank: 47

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ACET vs. BEAM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Adicet Bio, Inc. (ACET) and Beam Therapeutics Inc. (BEAM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ACET	BEAM	Difference
Sharpe ratio Return per unit of total volatility	-0.48	0.29	-0.77
Sortino ratio Return per unit of downside risk	-0.29	1.03	-1.32
Omega ratio Gain probability vs. loss probability	0.97	1.12	-0.15
Calmar ratio Return relative to maximum drawdown	-0.77	0.19	-0.96
Martin ratio Return relative to average drawdown	-1.40	0.42	-1.82
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ACET vs. BEAM - Sharpe Ratio Comparison

The current ACET Sharpe Ratio is -0.48, which is lower than the BEAM Sharpe Ratio of 0.29. The chart below compares the historical Sharpe Ratios of ACET and BEAM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ACET	BEAM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.48	0.29	-0.77
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.55	-0.29	-0.27
Sharpe Ratio (All Time) Calculated using the full available price history	-0.53	0.05	-0.58

Correlation

The correlation between ACET and BEAM is 0.35, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ACET vs. BEAM - Dividend Comparison

Neither ACET nor BEAM has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ACET vs. BEAM - Drawdown Comparison

The maximum ACET drawdown since its inception was -99.74%, which is greater than BEAM's maximum drawdown of -89.12%. Use the drawdown chart below to compare losses from any high point for ACET and BEAM.

Drawdown Indicators

	ACET	BEAM	Difference
Max Drawdown Largest peak-to-trough decline	-99.74%	-89.12%	-10.62%
Max Drawdown (1Y) Largest decline over 1 year	-63.28%	-38.15%	-25.13%
Max Drawdown (5Y) Largest decline over 5 years	-98.20%	-89.12%	-9.08%
Current Drawdown Current decline from peak	-99.71%	-82.16%	-17.55%
Average Drawdown Average peak-to-trough decline	-85.01%	-59.29%	-25.72%
Ulcer Index Depth and duration of drawdowns from previous peaks	34.83%	17.33%	+17.50%

Volatility

ACET vs. BEAM - Volatility Comparison

Adicet Bio, Inc. (ACET) has a higher volatility of 19.04% compared to Beam Therapeutics Inc. (BEAM) at 17.93%. This indicates that ACET's price experiences larger fluctuations and is considered to be riskier than BEAM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ACET	BEAM	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.04%	17.93%	+1.11%
Volatility (6M) Calculated over the trailing 6-month period	54.00%	53.97%	+0.03%
Volatility (1Y) Calculated over the trailing 1-year period	91.05%	78.23%	+12.82%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	90.36%	75.45%	+14.91%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	94.13%	80.57%	+13.56%

Financials